A recent study linking marijuana use to schizophrenia attracted widespread attention. Now that the excitement has died down, let's take a closer look at the science. How does Pfizer's weight-loss pill compare to Ozempic, the obesity treatment beloved celebrities the world over?
Join host Cameron English as he sits down with Dr. Chuck Dinerstein to break down these stories on Episode 43 of the Science Dispatch podcast:
Which Came First, the Cannabis or the Schizophrenia?Within the timeframe of the legalization of recreational cannabis, there's been a rise in cannabis “use disorder” and the diagnosis of schizophrenia. It's become a chicken or egg which-came-first problem. A new study suggests cannabis is the gateway, creating 15% of new cases of schizophrenia annually.
Will Pfizer's New Weight Loss Pill Silence the Ozempic Commercials?If you're one of the 100% of viewers who want to put a brick through your TV when one of the ceaseless, nauseating Ozempic ads comes on there's hope on the horizon. Pfizer has a pill that seems to work as well as the O-O-O-Ozempic injections. Perhaps this will shut up those wretched ads. A look at Pfizer's clinical trial data.